This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.
Androgen inhibitor Erleada (apalutamide) is Janssen’s follow-up to its older, blockbuster prostate cancer drug Zytiga (abiraterone acetate), which has now been hit by the loss of patent protection and
In the key secondary endpoint of overall survival, Lynparza reduced the risk of death by 31% compared to enzalutamide or abiraterone. ... Lynparza is the only PARP inhibitor to demonstrate overall survival versus enzalutamide or abiraterone for men with
Androgen inhibitor Erleada (apalutamide) is J&J’s follow-up up to big-selling prostate cancer drug Zytiga (abiraterone acetate), which has been hit by the loss of patent protection and
Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
therapy Zytiga (abiraterone acetate).
Zytiga (abiraterone acetate) or Pfizer’s Xtandi (enzalutamide).
More from news
Approximately 5 fully matching, plus 61 partially matching documents found.
outperforming J&J's Zytiga [abiraterone].
But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen
AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy
Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Real-world patients treated with abiraterone for post-chemotherapy metastatic castration-resistant prostate cancer survived longer with shorter treatment duration compared with patients in clinical trials.
Abiraterone. Zytiga. Janssen. Treatment of patients with metastatic castration-resistant prostate cancer. .
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...